BiogenBIIB obliterated Wall Street's first-quarter expectations Wednesday, helped by a nearly perfect sales beat sweep for its growth products. The most notable beat, according to RBC Capital Markets ...
After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, Biogen’s “new Biogen” is beginning to take shape. With 7% year-over-year sales ...
Biogen BIIB reported second-quarter 2025 adjusted earnings per share (EPS) of $5.47, which significantly beat the Zacks Consensus Estimate of $3.93. Earnings rose 4% year over year on a reported basis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results